Jefferies lowers Pediatrix Medical Group stock price target to $19 on eAPTC concerns

Published 06/08/2025, 17:54
Jefferies lowers Pediatrix Medical Group stock price target to $19 on eAPTC concerns

Investing.com - Jefferies lowered its price target on Pediatrix Medical (TASE:BLWV) Group (NYSE:MD) to $19.00 from $21.00 on Wednesday, while maintaining a Buy rating on the healthcare company’s stock. The company, currently trading at $14.02 with a market capitalization of $1.2 billion, maintains strong fundamentals with an EBITDA of $236.72 million over the last twelve months.

The price target reduction comes despite Pediatrix posting strong quarterly results, with EBITDA beats exceeding 20% for the last three quarters, which allowed the company to raise its fiscal year 2025 EBITDA guidance by $20 million at the midpoint.

Jefferies cited concerns about the lack of a clear path to extending the enhanced Advanced Payment Tax Credit (eAPTC) as the primary reason for the more conservative outlook, embedding a $19.3 million revenue and EBITDA headwind in its updated fiscal year 2026 estimates.

Despite the price target reduction, Jefferies raised its overall fiscal year 2026 estimates for Pediatrix, citing the company’s fiscal year 2025 outperformance as a contributing factor.

The firm remains bullish on Pediatrix Medical Group, pointing to the stock’s cheap valuation, strong execution, and significant share buyback opportunity as positive factors supporting the maintained Buy rating. Trading at a P/E ratio of 10.76x and generating a substantial free cash flow yield of 19%, InvestingPro analysis indicates the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report.

In other recent news, Pediatrix Medical Group reported strong financial results for the second quarter of 2025, surpassing analysts’ expectations. The company achieved an earnings per share (EPS) of $0.53, which was higher than the forecasted $0.42, resulting in a 26.19% positive surprise. Revenue also slightly exceeded projections, coming in at $468.84 million against the anticipated $464.37 million. These results underscore the company’s solid performance during the period. While the stock saw significant movement following the announcement, this article focuses on the earnings and revenue outcomes. The earnings beat signals a positive trend for Pediatrix Medical Group, as noted by analysts. Investors may find these developments noteworthy as they reflect the company’s financial health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.